PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast - John B. Buse, MD, PhD - An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes

John B. Buse, MD, PhD - An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes

07/05/19 • 40 min

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Previous Episode

undefined - Adrian Hernandez, MD, MHS - Recognizing and Treating Iron Deficiency in Patients With Heart Failure: Achieving Better Outcomes and Quality of Life

Adrian Hernandez, MD, MHS - Recognizing and Treating Iron Deficiency in Patients With Heart Failure: Achieving Better Outcomes and Quality of Life

Go online to PeerView.com/FCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in cardiology shares insight on recognizing and treating iron deficiency in patients with heart failure to achieve better outcomes and quality of life. Upon completion of this activity, participants should be better able to: Recognize the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life, Identify evidence-based guidelines and the latest clinical data on the efficacy and safety of currently available and emerging iron therapies for the management of ID in patients with HF, Apply evidence-based guidelines and the latest clinical data on available and emerging iron therapies to the treatment of ID in patients with HF.

Next Episode

undefined - Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.